Connect with us


3 Cannabis Stocks To Watch In July 2021



While investors wonder why stocks have fallen this week, some would now see buying opportunities in the stock market. Cannabis stocks might be worth a look now. With more federal laws supporting both the medical and recreational markets, the industry is now firing on all cylinders. Obviously, 18 states now allow the recreational use of marijuana by adults, while twice as many laws have been passed legalizing medical use. Does this mean that the industry has more room for further growth?

Well, Jefferies (NYSE: JEF) investment bank seems to believe so. Yesterday, analyst Owen Bennett started reporting on several cannabis companies, each with a buy rating. Among those he treated were Cresco Labs (OTCMKTS: CRLBF), Green Thumb Industries (OTCMKTS: GTBIF), and Trulieve Cannabis (OTCMKTS: TCNNF). It is noteworthy that, among other things, these stocks are currently posting gains of over 170% over the past year. However, Bennett argues that by then the value of some could double over the next year. In his words, “We believe this is a generation wealth opportunity with potential 12-month average expected gains across our entire coverage being over 100 percent.” Additionally, the company currently estimates that the U.S. cannabis market could be worth $ 64 billion by the end of the decade.

By and large, the cannabis industry continues to gain momentum regardless of stock performance. As the broader stock market retreats today, some top cannabis stocks could trade at more attractive valuations. With that in mind, could one of these cannabis players be your next big investment?

The best cannabis stocks to buy [Or Sell] In July

Canopy Growth Corporation

We’ll take a look at Canopy Growth Corporation (CGC) in a moment. In short, CGC is a diversified cannabis and cannabinoid based consumer products company. The company offers a wide range of products for both the recreational and medical markets. On the one hand, it markets high quality dried flowers, infused beverages, edibles and even vaporizers for adults. On the other hand, CGC also operates through its global medical marijuana brand, Spectrum Therapeutics. Through Spectrum, the company sells a range of medicinal cannabis products such as softgels, THC oils, and CBD oils. CGC estimates that Spectrum is the market leader in both the Canadian and German medical industries.

Given the impressive portfolio, I can understand if investors are interested in CGC stocks right now. Despite all of this, the company’s stock has been trading at a loss since the beginning of the year. Regardless of this, CGC continues to strengthen and expand its services. Just last month the company completed the acquisition of The Supreme Cannabis Company (Supreme). Well, to emphasize, the acquisition would give CGC access to Supreme’s global diversified medical cannabis portfolio. In addition, CGC would also purchase Supreme’s low-cost, scalable cultivation facility in Kincardine, Ontario. It’s safe to say that this is an important step by CGC on the operational front.

Overall, David Klein, CEO of CGC, believes the move will strengthen CGC’s leadership position in the Canadian recreational cannabis market. He names the addition of Supreme’s premium product brand 7ACRES as a key growth driver for CGC’s premium product segment. All in all, are you going to add CGC stocks to your portfolio?

Source: TD Ameritrade TOS

Continue reading

Hexo Corporation

After that, we have an award-winning licensed manufacturer of innovative products for the global cannabis market, Hexo Corporation. Similar to our previous entry, Hexo now also has significant activity in both the adult use and medicinal cannabis markets. On the consumer side, it works through its brands HEXO, UP Cannabis, Namaste and REUP, among others. In terms of the medical consumables business, Hexo primarily serves the Canadian, Israel and Malta markets. Not to mention, it also serves the Colorado market through a joint venture operation with Molson Coors (NYSE: TAP). This company mainly markets its goods through the high-quality Powered by HEXO brand.

With the closing bell on Thursday, the HEXO share expects growth of over 26% since the beginning of the year. Could it have more room for further growth? If anything, the company is now working hard to expand its presence in the US market. Last week Hexo announced the successful purchase of its first US manufacturing facility. Specifically, it now owns a 50,000 square foot facility in Fort Collins, Colorado. This would be a smart move by Hexo. Accordingly, the strategically located facility would continue to support its current and future US operations. In particular, Hexo also notes that the facility is capable of producing its full line of cannabis products and has a wide variety of operational options.

In addition, this move follows the recent acquisition of Zenabis Global Inc., a Canada-based breeder of medicinal and recreational cannabis. All in all, Hexo seems to be in full swing across the board. Given the company’s current momentum, would you consider HEXO stock a top buy right now?

Cannabis stocks (HEXO stock)Source: TD Ameritrade TOS

[Read More] The best stocks to buy right now? 5 Aerospace Stocks You Should Know About

Curaleaf Holdings Inc.

Another top name in the cannabis industry to know by now would be Curaleaf Holdings Inc. First of all, the company manufactures and sells cannabis throughout the North American region and operates pharmacies in over 20 states. At the same time, Curaleaf has a massive delivery and distribution network in Europe under its Curaleaf International division. In fact, it is now the largest vertically integrated cannabis company in the European market. All of this makes Curaleaf a leading international provider of consumer cannabis products. Now that CURLF stock has risen over 130% over the past year, could it have any more headroom for the future?

That remains to be seen, but it is clear that Curaleaf does not remain idle. This is evident as the company rolled out two major operational updates this week. On the one hand, Curaleaf has been cooperating with Agrify Corporation (NASDAQ: AGFY) since Tuesday. The duo are now part of a long-term research and development partnership exploring ways to refine growing techniques. Given Agrify’s experience as a developer of world-class cannabis growing solutions, this seems like a win for Curaleaf. CEO Joseph Bayern sums it up best: “We believe this research will help further improve our understanding of the conditions necessary to optimize a plant’s genetic potential.”

Second, the company’s Curaleaf International unit is now making waves in the Israeli market. As of yesterday, the company had exported over a ton of medicinal cannabis to BOL Pharma in Israel. To explain, BOL was among the first licensed medicinal cannabis growers in the region. Given the current strong partnership between the two, Curaleaf’s presence in the Israeli market would now be remarkable. Will you be investing in Curaleaf stock as Curaleaf seeks to improve its business on multiple fronts?

best cannabis stocks (CURLF stock)Source: TD Ameritrade TOS

The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Study Suggests Hemp Extract Is An Effective Weight-Loss Aid



A proprietary hemp extract shows promise as a supplement for promoting weight loss, according to a study funded by a grant from the National Institutes of Health. Data from the double-blind, placebo-controlled study showed that all 100 participants who took Nitro-V hemp extract daily lost weight and lost up to 22 pounds over 90 days. The minimum weight loss for those taking the supplement was 5 pounds, while 64% of participants in the placebo group either gained weight or saw no change.

The study participants who took the hemp extract, which is high in cannabidiol (CBD), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), and other cannabinoids, also showed improvements in other metabolic health metrics and important wellness indicators without changing their diet and exercise habits to change. Participants who took Nitro-V saw their body mass index (BMI) decrease an average of three points and lost an average of 2.4 inches from their waist measurements. On average, the study participants in the placebo group gained weight and saw that their BMI remained the same.

Cannabis (hemp) extract.


Almost 75% of Americans are overweight

According to data from the CDC, more than 73% of adults 20 years or older in the United States are overweight or obese. The health risks associated with obesity can be serious and include heart disease, diabetes, and high blood pressure. Additional CDC data shows that between 2013 and 2016, more than 49% of American adults reported trying to lose weight in the past 12 months.

“Those working to lose weight and improve their overall health are looking for every benefit they can find to help them stick to their exercise and nutrition plans,” said Arthur Jaffee, CEO of Nitro-V manufacturer ECS Brands , in a press release. “Given the results of these studies, we believe that Nitro-V could be the tool to help many achieve their weight loss potential and feel better.”

To conduct the clinical study, which had not yet been published in a peer-reviewed journal, the researchers assembled a group of 125 subjects to participate in the research. A total of 100 participants received either one or two 50 mg servings of Nitro-V daily, the remaining 25 participants received a placebo. Study participants were not told that they were participating in a weight loss study and that they had not changed their diet or exercise habits.

At the beginning and end of the 90-day study period, participants visited the Mayo Clinic campus in Scottsdale, Arizona and completed standardized surveys on health determinants such as diet, appetite, anxiety, and pain. The researchers also monitored the subjects’ weight, BMI, waist circumference, and vital signs, and performed full blood tests to measure blood sugar, cholesterol, and organ health, as well as other diagnostic tests. A statistician analyzed the data collected during the study to identify trends and evaluate the importance of the results. The research was funded by a small business owned by the National Institutes of Health and conducted by a contract researcher with 20 years of experience in product safety studies.

Each softgel microcapsule serving of Nitro-V contains 50 mg of hemp extract with a combination of cannabinoids such as CBD, THCV and CBDV in an organic hemp seed oil base. The solvent-free hemp extract contains the full cannabinoid profile of the source plant, including less than 0.1% THC. Further processing increases the THCV and CBDV levels in the supplement.

The “thin cannabinoid”

Cannabinoids from cannabis, including hemp, act on the body’s endocannabinoid system, which helps maintain physiological, cognitive, and emotional stability. Research has shown that THCV can act as an effective appetite suppressant, which has earned it the nickname “thin cannabinoid”. Other studies have shown that THCV can also help regulate blood sugar levels. THCV also has anti-inflammatory and antispasmodic properties.

Nitro-V hemp extract softgels from ECS Brands.

Photo courtesy of ECS Brands

Jaffee notes that recent research has shown that CBD and THCV can affect lipid and glucose metabolism in animals, both important factors in maintaining a healthy weight. The study also found that CBD had several positive effects on hyperglycemia, largely due to its anti-inflammatory and antioxidant properties. Further evidence from animal studies shows that CBD modulates the cardiovascular response to stress, which plays a role in weight gain and loss. However, the link between CBDV and weight loss is “less direct,” he says.

“Research shows that CBDV is a powerful anti-inflammatory agent that can play a role in both appetite and weight,” Jaffee wrote in an email. “Reduced inflammation in the body helps optimize the performance of the metabolic organs, and fat cells themselves are metabolic organs. Inflamed fat cells do not work properly and can contribute to unhealthy weight gain. “

The Nitro-V study also showed several other changes in the health and well-being of the participants, including many with the potential to affect weight loss. Participants who used the supplement in the study showed a 61% reduction in hunger and had fewer food cravings. In addition, all 37 study participants who took Nitro-V and were classified as prediabetic had their blood sugar levels returned to normal by the end of the 90-day study. The subjects also reported less difficulty resisting food cravings and showed improvements in sleep, happiness, and anxiety. Research also showed that the hemp extract was well tolerated and safe, with blood tests showing that all safety and toxicity levels remained within healthy, normal ranges.

A hemp field in rural Belgium.


While the study was designed to examine the effects of Nitro-V on weight loss, Jaffee says the data suggests the supplement may have other health and health benefits as well.

“The ultimate goal of the study was to identify the overarching power of the ECS system, and the results indicate effects beyond weight loss and appetite suppression,” he writes. “But as with all cannabinoid and ECS researchers today, we still have many unanswered questions about how interactions between cannabinoids and the ECS lead to health improvements.”

Continue Reading


Could CBD Oil Help with Nausea?



When it comes to the CBD industry, misinformation is rampant. There are too many brands out there trying to make quick money in a phenomenally fast growing market. With a lot of money at stake, these companies are less concerned about what they can do for their customers and more concerned about their profit margins.

The benefits of CBD are known due to the relentless research of dedicated scientists. However, the actions of certain brands lead the general public to remain skeptical.

My advice is to avoid brands that claim that their CBD oil “treats” everything. Unless the cannabinoid is approved by the FDA for medical treatment, no brand is allowed to make any medical claims. However, there is no question that CBD is a potential life changer for many people, for example against nausea. Let’s find out more.

What is nausea?

It is usually classified as a stomach discomfort that makes you want to throw up. It affects a wide variety of people and can have a variety of causes. Common reasons for nausea are:

  • heartburn
  • GERD
  • An infection or a virus
  • Motion sickness
  • Extreme pain
  • Medication

It’s important to remember that nausea is not a disease in itself. Instead, it’s your body’s response to one of a number of conditions. Although it feels awful, nausea is often necessary for your body to fight off unwanted invaders.

Although there are several anti-nausea drugs on the market, there is evidence that CBD may be effective against nausea.

How could CBD help with nausea?

THC is the most common intoxicating cannabinoid found in marijuana. It’s also available in small quantities in hemp. THC is known to create a high, and it binds to endocannabinoid receptors in the brain and spinal cord.

CBD works on these receptors too, but in a different way. First of all, it doesn’t bind directly to the CB1 and CB2 receptors. This helps explain why it doesn’t induce an intoxicating high. CBD helps the body produce higher levels of endocannabinoids like anandamide.

What does the research say?

Currently, much of the research on CBD for nausea is based on people with cancer. Nausea and vomiting are common side effects of chemotherapy. A study published in 2016 examined how cannabinoids can regulate acute and anticipatory nausea. The researchers found that a combination of THC and CBD could provide some relief to cancer patients undergoing chemotherapy.

The American Cancer Society actually puts cannabinoids on its list of drugs to use to treat nausea and vomiting. It suggests that these compounds may be useful in cases where traditional anti-nausea medications are ineffective.

A 2011 review of animal studies also looked at how cannabinoids can regulate nausea and vomiting. The researchers found that CBD was potentially useful against nausea due to its interaction with serotonin receptors. Serotonin is a hormone that affects our mood, behavior, and wellbeing.

THC is potentially more effective at reducing the effects of nausea. However, it causes a high intoxication and is not legal in over a dozen US states. It’s also not legal in many countries around the world. Although CBD is not strictly legal in America, it is widely used and tolerated. It is also widely used around the world, with many nations specifically saying that it is legal.

What types of CBD should I use for nausea?

You will likely get more benefits from CBD for nausea by trying a full-spectrum product. This is because research suggests that the presence of THC might increase its anti-nausea effects. A full-spectrum CBD product contains dozens of compounds and terpenes. However, in the United States, it cannot contain more than 0.3% THC. In the UK, the maximum THC content is 0.2%.

When you feel sick, it makes sense to avoid anything that could make you feel like you are vomiting. While some people can tolerate edibles or oils, others cannot. CBD capsules are another option. They have no taste and are easy to swallow. You could try vaping CBD for a faster effect, but your stomach may not like it!

It also makes sense to start with a relatively low dose and work your way up. Start with 5-10 mg of CBD and increase it as needed.

Final thoughts on CBD for nausea

According to the research available, there is plenty of evidence that CBD could be effective against nausea. While most of the studies are on cancer patients recovering from chemotherapy, you may find that CBD works for your nausea. There are also many other potential benefits of CBD that are worth exploring.

When trying out CBD for nausea, you need to carefully consider your method of consumption. Buy a moderate amount first to see how you react. If you can handle it, you can buy more and possibly increase the amount you consume.

Image by unbekanntuserpanama from Pixabay

Continue Reading


Biomedican receives approval notification from the U.S. Patent Office on its first patent — Greenway Magazine



Biomedican has received notification from the U.S. Patent Office that its first patent has been granted and will be issued in the coming months. This is the first patent ever issued using Yarrowia Lipolytica to make cannabinoids.

“This is a very important milestone for Biomedican as it will be the first patent issued using Yarrowia Lipolytica to make cannabinoids. Yarrowia Lipolytica is an oily yeast that naturally produces large amounts of oil. Our variety can produce over 80% of the oils from dry cell mass. The cannabinoid pathway relies on the same precursors that are needed for oil production. Cannabis produces cannabinoids in oil droplets on trichomes. Enzymes that convert CBGA to CBDA, CBCA, and THCA are required for two phases to interact: oil and water. Our yeasts have oil droplets inside, which are natural stores for cannabinoids. Basically, we completely imitate the natural production process of our yeast, ”says CEO Dr. Maxim Michejew, Ph.D.

To the best of our knowledge, many other companies have problems making late-stage enzymes that work in baker’s yeast, E. coli, pitchia pastoris, and microalgae.

Most cannabinoids are known for their antifungal and antibacterial properties. This means that they are toxic to a wide variety of bacteria, yeasts, and fungi. In fact, several publications have shown the toxicity of cannabinoids to cannabis plants as well. Because of this, cannabis produces cannabinoids outside of cells on specialized cells – trichomes.

Yarrowia Lipolytica is famous for its high resistance to toxic compounds. Cannabinoids are not toxic to Yarrowia Lipolytica. In our experiments, the wild type of YL was able to use cannabinoids as a carbon source. Basically, she ate it instead of sugar with no toxic effects. We had to modify our strain to prevent cannabinoid use.

“As a result of this patent and three other patents pending, our varieties of cannabinoids can produce up to 5% from the dry cell mass. Higher yields mean lower costs for production and downstream cleaning. The main problem facing most companies in this space is low yields and their inability to make olivetolic acid, which is a critical compound for making cannabinoids. If you cannot make olivetolic acid, we believe that you will not be able to compete in this market as you will be forced to buy olivetolic acid as an additive, which will significantly increase the cost of production. We believe that this gives us a clear path to be the most cost-effective manufacturer in the field of biosynthetic cannabinoids ”, says CEO Dr. Maxim Mikheev, Ph.D.

Biomedican has filed three additional patents which are a very unique technology to produce the highest quality 99% pharmaceutical cannabinoids, bioorganic, zero toxins and impurities at 70-90% less cost than current prices and 90% less natural resources and energy than growers consume. Biomedican has successfully biosynthesized CBG / CBGA, THCV / THCVA. Current research and development to manufacture CBN / CBNA and THCA will be completed by the end of 2021.

“The patenting of the use of Yarrowia Lipolytica to manufacture cannabinoids gives Biomedican a significant competitive advantage in the biosynthetic cannabinoid market. Not only does Yarrowia Lipolytica produce significantly higher yields than other technologies, but it behaves similarly to the cannabis plant, meaning Biomedican’s technology is very applicable and scalable to produce any cannabinoid with a viable market. We expect to register additional patents to further expand our technological lead and look forward to further approvals of pending patents. The biosynthesis market is one of the fastest growing markets in the world, projected to reach $ 25 billion by 2025, and Biomedican is positioned to lead the field, ”said President Dennis O’Neill.

Cannabinoids are naturally occurring compounds found in the cannabis sativa plant. The two most famous cannabinoids are CBD and THC, which currently make up the largest share of the industry. In addition, scientists have already discovered hundreds of cannabinoids. Few of them have an intoxicating effect; In contrast, most cannabinoids offer various health benefits. As its popularity grows and clinical trials begin, new potential uses are constantly being discovered.

However, many cannabinoids are difficult to isolate from the cannabis sativa plant due to their rarity. Specialists have called them rare cannabinoids, and many of them offer unique properties, uses, and benefits. Research into these rare compounds has led to endless possibilities for consumer and medical applications.

Continue Reading